Home » News » 01/06 » Roche forms inflammatory disease collaboration

Roche forms inflammatory disease collaboration

Date published: 11/01/2006

Roche has signed a research collaboration with the US biotech firm Amira Pharmaceuticals aimed at finding treatments for inflammatory diseases.

As a part of the agreement Roche will use its screening capabilities to investigate three mutually agreed targets in the field of inflammatory diseases while Amira, a inflammatory disease specialist, will use its expertise to develop the compounds generated. Roche will also take opt-in rights on two compounds, while under a separate agreement Amira may license two clinical programmes from Roch in exchange for equity, milestones and royalties.

Roche global head of Pharma Partnering Peter Hug said: "In the past, we referred to a 'win-win' alliance between pharma and biotech partners.

"Through this new model, we have created a 'win-win-win' deal structure where three main players, Roche, Amira and the venture community, are all benefiting from a joint effort to develop potential new medicines for patients."

Under the research collaboration Amira could receive up to $287 million in total payments, while Roche could receive up to $20 million from Amira's possible licensing clinical programmes.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.